Reeves, S;
Bertrand, J;
D'Antonio, F;
McLachlan, E;
Nair, A;
Brownings, S;
Greaves, S;
... Howard, R; + view all
(2016)
A population approach to characterise amisulpride pharmacokinetics in older people and Alzheimer's disease.
Psychopharmacology
, 233
(18)
pp. 3371-3381.
10.1007/s00213-016-4379-6.
Preview |
Text
A population approach to characterise amisulpride pharmacokinetics in older people and Alzheimer's disease.pdf - Published Version Download (1MB) | Preview |
Abstract
Introduction Current prescribing guidelines for the antipsychotic amisulpride are based largely on pharmacokinetic (PK) studies in young adults, and there is a relative absence of data on older patients, who are at greatest risk of developing adverse events. Methods This study aimed to develop a population PK model for amisulpride specifically in older people, by combining data from a richly sampled phase 1, single (50 mg) dose study in healthy older people (n = 20, 65–79 years), with a clinical dataset obtained during off label, low-dose (25–75 mg daily) amisulpride prescribing in older people with Alzheimer’s disease (AD) (n = 25, 69–92 years), as part of an observational study. Results After introducing a scaling factor based on body weight, age accounted for 20 % of the inter-individual variability in drug clearance (CL), resulting in a 54 % difference in CL between those aged 65 and those aged 85 years, and higher blood concentrations in older patients. Discussion These findings argue for the consideration of age and weight-based dose stratification to optimise amisulpride prescribing in older people, particularly in those aged 85 years and above.
| Type: | Article |
|---|---|
| Title: | A population approach to characterise amisulpride pharmacokinetics in older people and Alzheimer's disease |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1007/s00213-016-4379-6 |
| Publisher version: | http://dx.doi.org/10.1007/s00213-016-4379-6 |
| Language: | English |
| Additional information: | © The Author(s) 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
| Keywords: | Science & Technology, Life Sciences & Biomedicine, Neurosciences, Pharmacology & Pharmacy, Psychiatry, Neurosciences & Neurology, Amisulpride, Elderly, Alzheimer's disease, Age, Population pharmacokinetics, Antipsychotic, ORGANIC CATION TRANSPORTERS, ANTIPSYCHOTIC-DRUGS, SCHIZOAFFECTIVE DISORDER, CONSENSUS GUIDELINES, RECEPTOR OCCUPANCY, PLASMA AMISULPRIDE, DEMENTIA, SCHIZOPHRENIA, UPDATE, PHARMACODYNAMICS |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > Division of Psychiatry UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > Div of Biosciences |
| URI: | https://discovery.ucl.ac.uk/id/eprint/1509337 |
Archive Staff Only
 |
View Item |
